Lung cancer remains the leading cause of cancer-related deaths worldwide, but a concerning trend is emerging: an increasing number of diagnoses among individuals who have never smoked. This shift necessitates a re-evaluation of traditional lung cancer models and a focused effort to understand the unique biological factors at play in this growing population. Researchers are now investigating how genetics, environmental exposures and innovative screening methods could lead to earlier detection and improved outcomes for those affected by lung cancer in never smokers (LCINS).
Historically, lung cancer research and prevention efforts have centered on smokers. However, LCINS represents a significant and rising percentage of cases, even though the absolute numbers remain lower than those linked to tobacco use. This distinct form of the disease often presents with different characteristics, including a lower tumor mutational burden and a higher prevalence of actionable genetic mutations, potentially impacting treatment response. Understanding these differences is crucial for developing targeted therapies and effective screening protocols.
The Role of Genetics and Inherited Risk
Identifying individuals at elevated risk of LCINS is challenging, but emerging research points to both inherited and acquired biological predispositions. Studies have linked variations in genes like EGFR, TP53, ATM, and those within the APOBEC3 family to an increased risk of developing the disease. Specifically, mutations such as EGFR p.Thr790Met (T790M) can significantly elevate lifetime risk and potentially lead to the development of multiple lung lesions, according to research published in the journal Trends in Cancer. Population-specific genetic factors, such as deletions in the APOBEC3A/B genes, also appear to increase susceptibility in certain ethnic groups, suggesting that genetic screening could eventually play a role in risk-adapted surveillance.
Beyond inherited factors, a condition known as clonal hematopoiesis of indeterminate potential (CHIP) is gaining attention as a potential risk factor. CHIP involves mutations in hematopoietic stem cells, affecting genes like DNMT3A, TET2, and ASXL1. Individuals with a high proportion of cells carrying these mutations may face an increased risk of solid tumors, including lung cancer, independent of smoking status. The mechanism behind this link appears to involve chronic inflammation and elevated levels of interleukin-1β (IL-1β), though the effectiveness of anti-IL-1β therapies remains under investigation.
Environmental Factors and the “Exposome”
The cumulative impact of environmental exposures throughout a person’s life – known as the “exposome” – is increasingly recognized as a critical factor in LCINS development. Radon exposure, particularly in poorly ventilated indoor spaces, is a well-established carcinogen. Although historically linked to occupational exposure in miners, residential radon remains a public health concern. Exposure to secondhand smoke also increases lung cancer risk in never smokers by approximately 20–25%, though tumors in these individuals may not exhibit the same mutational signatures as those in smokers, suggesting a different underlying mechanism.
Air pollution, specifically fine particulate matter (PM2.5), is another significant environmental risk factor. High PM2.5 exposure correlates with a greater mutation burden, mutations in the TP53 gene, telomere shortening, and inflammation within the lungs. This pollution-induced inflammation, particularly involving IL-1β signaling, appears to promote tumorigenesis. However, accurately assessing risk is complicated by variations in exposure levels, especially in rapidly urbanizing areas.
Challenges and Advances in Early Detection
Early detection is paramount in improving lung cancer outcomes. Low-dose computed tomography (LDCT) screening has demonstrated a 20% reduction in lung cancer mortality among heavy smokers. However, applying LDCT to never smokers is more complex due to the difficulty in defining high-risk individuals and concerns about false positives, overdiagnosis, and cost-effectiveness. A clinical trial in Taiwan identified an elevated risk among never smokers with a first-degree family history of lung cancer, leading to an expansion of national screening criteria. Preliminary data suggest LDCT may be effective in select high-risk subgroups, such as Asian women with a familial predisposition, but further research is needed.
Emerging multi-cancer early-detection blood tests, which analyze circulating tumor DNA, are also under investigation, but their sensitivity for detecting highly early-stage lung cancer remains limited. Prevention strategies, including targeted therapies, immunotherapies, and cancer vaccines, are also being explored, particularly for individuals whose tumors harbor actionable genetic mutations.
LCINS represents a growing global health challenge that demands distinct diagnostic, screening, and therapeutic approaches. Integrating genetic susceptibility, clonal hematopoiesis, family history, and environmental exposures into comprehensive risk models may enable more precise screening and prevention strategies. Continued research is essential to advance our understanding of LCINS and develop tailored interception strategies to reduce mortality in this underrecognized patient population.
Disclaimer: This information is intended for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
What are your thoughts on the potential for genetic screening to identify individuals at higher risk of lung cancer, even without a history of smoking? Share your perspectives in the comments below.
